Kornimate/medical-research-clean huggingface dataset:
the effect of myofascial induction and therapeutic pain education in chronic low back pain

Conditions: Back Pain

Summary: the aim of this study was to investigate the effects of therapeutic pain education and myofascial induction therapy on pain and function in patients with chronic low back pain. in the literature, studies on myofascial induction therapy in patients with chronic low back pain are very limited and there is no study comparing therapeutic pain training.

lumbar pain has become a major health problem which is growing and is very common in all societies and negatively affects the full well-being of the individual. it has been reported that 80% of the population experienced low back pain at any time in their lives. the prolongation of this painful process affects the physical, mental and psychological state of the patient and limits its daily functions. the acute or chronic pain determines the nature and duration of pain. low back pain lasting 12 weeks or more is defined as chronic. in chronic diseases, lumbar pain, which is the first one, restricts the daily activities of the person due to current chronic pain or deterioration of functional status and causes loss of labor force. myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. the approach aims at global recovery, local correction and painless body use. superficial procedures are directed to surface and / or local restrictions that can be directly detected by palpation. deep myofascial induction therapy is a method that eliminates the limitations of the myofascial system and the three-dimensional pressures. therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. the neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. changes the patient's olab viewpoint to pain. for example, the patient believes that the cause of pain is caused by tissue damage. the patient who receives pain education understands that the cause of pain is the hypersensitive central nervous system. as a result, the patient's fear avoidance behavior decreases and he starts to move more easily. because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.

Eligibility criteria:
inclusion criteria: * between 25-65 years old * low back pain for at least 12 weeks * physical therapy in the last 1 month * there is no other disease that may cause low back pain. exclusion criteria: * stem pressure associated with pain * having severe discopathy * available compression fracture * to have rheumatic or inflammatory disease that may cause back pain.
a study of ly3502970 in participants with obesity or overweight with weight-related comorbidities

Conditions: Obesity; Overweight and Obesity

Summary: the main purpose of the study was to assess the effect of ly3502970 in participants who have obesity or are overweight.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) of ≥30-kilogram square meter (kg/m²) * have a bmi ≥27 kg/m² and \<30 kg/m² with at least 1 of the following weight-related comorbidities eg; \[have hypertension, or dyslipidemia, cardiovascular disease\] * have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss) exclusion criteria: * have any prior diagnosis of diabetes * have a prior or planned surgical treatment for obesity * have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity * have renal impairment measured as estimated glomerular filtration rate (egfr) \<30 milliliter (ml)/minute (min)/1.73 m² * have a history of acute chronic pancreatitis * have a history of significant active or unstable major depressive disorder (mdd) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years note: participants with mdd or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications. within 3 months prior to screening: * have poorly controlled hypertension * have history of acute myocardial infarction * have history of cerebrovascular accident (stroke) * had hospitalization due to congestive heart failure (chf) * have cancer * have human immunodeficiency virus (hiv) and/or positive hiv antibodies historically or at screening * have hepatitis b and/or positive hepatitis b surface antigen
a phase iii study of bms-512148 (dapagliflozin) in patients with type 2 diabetes who are not well controlled on metformin alone

Conditions: Type 2 Diabetes

Summary: the purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with type 2 diabetes that is not well controlled on metformin alone. the safety of this treatment will also be studied.


Eligibility criteria:
key inclusion criteria * males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic control * participants who have been receiving metformin at a total daily dose ≥1500 mg per day for at least 8 weeks * c-peptide ≥1.0 ng/ml * body mass index ≤45.0 kg/m\^2 * serum creatinine level \<1.50 mg/dl for men or \<1.40 mg/dl for women. key exclusion criteria * aspartate aminotransferase and/or alanine aminotransferase level \>3.0 times the upper limit of normal * serum total bilirubin level \>2 mg/dl * creatinine kinase level \>3 times upper limit of normal * symptoms of severely uncontrolled diabetes * serum creatinine level ≥1.50 mg/dl for men or ≥1.40 mg/dl for women * currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases

Keywords: diabetes mellitus, type 2 diabetes mellitus endocrine system diseases glucose metabolism disorders metabolic diseases metformin hypoglycemic agents pharmacologic actions physiological effects of drugs
utilizing mri for earlier diagnosis of rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: mri has been shown to be helpful in identifying patients who present with undifferentiated inflammatory arthritis who will develop ra within a one year follow up period. the absence of other clinically apparent symptoms often causes delays in diagnosis of ra. the use of the mri in conjunction with the physical examination has the potential to reduce diagnostic delay. earlier diagnosis would allow for earlier treatment implementation for better patient outcomes.


Eligibility criteria:
inclusion criteria: ≥ 18 years old undifferentiated inflammatory arthritis suspected to be early ra (≥1 joint with synovitis and ≥1 other tender joint) symptom duration ≤1 year exclusion criteria: unwillingness or inability to return to mayo clinic rochester for research follow-up visits current or previous use of dmards taking ≥10 mg of prednisone a day contraindications to contract enhanced mri history of another definite autoimmune or inflammatory rheumatic disease history of psoriasis history of inflammatory bowel disease unsuitably as deemed by the principal investigator
a study to investigate the effect of solabegron (gw427353) on gastrointestinal transit in healthy volunteers

Conditions: Irritable Bowel Syndrome (IBS)

Summary: this study will test the hypothesis that gw427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.


Eligibility criteria:
inclusion criteria: * subjects with no evidence of current or past history suggestive of gastrointestinal disease or disorder or medical illness that could compromise interpretation of the study. * no clinically significant laboratory results collected at the screening visit * men: body weight greater than or equal to 50kg (110 lbs) * women: body weight greater than or equal to 45kg (100 lbs) * bmi between 18.5 - 35 kg/m2 exclusion criteria: * females who are nursing or pregnant. * history of inflammatory bowel disease * history of gastric ulcers within 12 months of signing the informed consent form * tobacco users

Keywords: gw427353 b3-adrenergic receptor agonist irritable bowel syndrome (ibs) pharmacokinetics tolerability gastrointestinal transit
aryotrust® (trastuzumab) safety study

Conditions: Breast Cancer

Summary: this study was a phase iv, observational, multicenter, single-arm, open-label, post-marketing surveillance study for the assessment of aryotrust safety in iranian her2-positive breast cancer patients undergoing adjuvant chemotherapy regimens.

the present study is an observational, multicenter, non-interventional, single-arm, open-label pms study conducted in iran. no control groups are included in the study design. the objective of this pms study is to monitor and assess the safety of aryotrust in patients with non-metastatic her2-positive breast cancer in adjuvant setting over a period of 27 weeks. treatment with aryotrust in this study is defined as the administration of 6mg/kg aryotrust, every 3 weeks during the 27 weeks of the study period.

Eligibility criteria:
inclusion criteria: * patients with her2-positive breast cancer undergoing adjuvant chemotherapy regimens exclusion criteria: * patients who had received trastuzumab as part of their therapy or were not candidates for treatment continuation after adjuvant chemotherapy

Keywords: trastuzumab safety aryotrust breast cancer adjuvant chemotherapy
research interest antiphospholipid in predicting embolic risk during infective endocarditis

Conditions: Infective Endocarditis

Summary: embol-ei (research interest antiphospholipid antibody for embolic risk prediction in infective endocarditis) is a prospective cohort study with a biological collection. the main objective is: to re-evaluate the potential value of antiphospholipid (apl) antibodies as predictors of embolic events in infective endocarditis (ie) in the light of the improved current knowledge on these apl. the seconds objectives are: other plasma biomarkers of hemostasis (coagulation activation markers: d-dimer fragment 1 + 2 of prothrombin; endothelial biomarkers: plasma levels of von willebrand factor) will be taken into account in the analysis, and interest in predicting embolic risk, alone or in combination with apl will be investigated.

criteria of inclusion * patient hospitalized in the university hospital of nancy with an endocarditis some as modified duke criteria by li. the patient is eligible if it is considered and treated as a case of infective endocarditis by physicians ensuring its management. the application of the diagnostic classification duke criteria modified by li is made after the collection of all the data at the output of the patient. will be retained for the analysis of patients meeting certain infective endocarditis. clinical, microbiological data, derived from complementary therapies and scalable examinations (including the endpoint) were collected during the hospital stay by doctors that support helped a patient technician clinical studies. each application is reviewed by a multidisciplinary panel of two experts for validation. once validated record, the data collection schedule is sent to the centre d'investigation clinique 1433 epidémiologie clinique (cic-ec) to be entered on a database. a blood sample is taken from each patient at admission. these samples are packaged and stored in a collection. the serum used in search - called anticardiolipin (ac) immunoglobulin g (igg) and immunoglobulin m (igm) isotype by elisa.

Eligibility criteria:
inclusion criteria: * all the patients admitted either in the infectious department, in the cardiology department or in the intensive care unit of the university hospital of nancy and treated for ie. exclusion criteria: * patients with a previously known apl syndrome or illness frequently associated with apl syndrome (such as lupus) * patients with a delay between blood sample and diagnosis of ie longer than 21days * patients who had no symptomatic embolic events and no imaging procedure to detect an asymptomatic embolic event
the impact of a modified probe tip design on patient perception of discomfort on probing and clinical parameters using the florida probe® system

Conditions: Periodontitis; Diagnoses Disease

Summary: patient perception of pain on periodontal probing using a controlled-force, electronic probe was not significantly affected by the use of a modified (ball-end) probe tip design except for in the maxilla, where a standard straight probe tip appeared to be more comfortable for patients.

recordings of periodontal probing pocket depth (ppd) and probing attachment level (pal) are utilized in diagnosis of periodontal disease and monitoring of disease progression. manual probing presents reproducibility and accuracy issues based on features such as probe tip design, force applied by the operator and inflammatory status of the periodontal tissues. evidence from the literature suggests that some patients may determine periodontal probing to be a painful experience. the aims of this study are to evaluate the suitability of a new titanium probe tip for periodontal probing, and to evaluate pain on periodontal probing, in comparison to the existing probe tip used in the florida probe® system. the study will be a randomized, blinded, split-mouth controlled trial. twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. one half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip; the opposing jaw will be probed using the new trial tip. at a second visit (within 2 weeks), prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit. on each occasion, patients will report on pain on probing utilizing two ungraded 100mm horizontal visual analogue scales (vas) representing upper and lower jaws of the mouth. periodontal probing depth measurements will be compared to assess the reproducibility of the two probe tips. mean vas values and standard deviations will be calculated for the test and control groups. data analysis will be conducted using a non-parametric statistical model (mann-whitney u test). inclusion criteria: * adult patients: age greater than 18 years. * at least 4 tooth sites with periodontal probing pocket depth (ppd) greater or equal to 4mm. exclusion criteria: - patients using ongoing daily chronic analgesic medications (nsaids etc) for over 3 months.

Eligibility criteria:
inclusion criteria: * age greater than 18 years. * must have 4 tooth sites with periodontal probing pocket depth (ppd) greater or equal to 4mm. exclusion criteria: - daily use of analgesic medications (nsaids etc) for over 3 months.
evaluating the efficacy of vardenafil in subjects with erectile dysfunction (ed) administered 12, 18 or 24 hours prior to intercourse

Conditions: Erectile Dysfunction

Summary: erectile dysfunction (ed) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. however, there remains no prospectively obtained data on the maximal time of effectiveness of vardenafil. the goal of the current study was to determine if vardenafil will significantly increase the percentage of successful intercourse attempts from 12 to 24 hours following dosing. a total of three time points 12, 18, and 24 hours were assessed in this pilot study to better quantify the effect of vardenafil.


Eligibility criteria:
inclusion criteria: * men \>/= 18 years of age * ed \>/= 6 months * stable sexual relationship for \> 6 months exclusion criteria: * primary hypoactive sexual desire * history of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month * nitrate therapy * other exclusion criteria apply according to the summary of product characteristics

Keywords: erectile dysfunction vardenafil
use of an oxidized regenerated cellulose after thyroid surgery: a prospective, randomized study

Conditions: Thyroidectomy

Summary: the purpose of this study is to evaluate the effects and safety of oxidized, regenerated cellulose as an absorbable adhesion barrier after thyroidectomy.


Eligibility criteria:
inclusion criteria: * operable thyroid neoplasm exclusion criteria: * a history of previous neck surgeries or uncontrolled medical diseases such as hyperthyroidism, diabetes, and hypertension * administration of non-steroidal anti-inflammatory drugs (nsaids) or anti-platelet agents within 1 week before surgery

Keywords: postoperative adhesion after thyroidectomy
treatment effect of tamoxifen on patients with dmd

Conditions: Duchenne Muscular Dystrophy

Summary: duchenne muscular dystrophy (dmd) is a progressive devastating disease that affects mainly boys, with an incidence of about 1:3,500 live births. the pathology of dmd is a result of non-repaired muscle damage that leads to muscle-tissue replacement by scar tissue, a process known as fibrosis. currently, there is no effective treatment for the disease. the only therapy offered to these boys are steroids which slightly delayed the disease progression. the boys lose their ability to walk at around the age of 12, and die in the 4th decade of life from severe heart and lung problems. in this study investigators will test the efficacy of tamoxifen treatment in ambulatory dmd boys. tamoxifen is a drug used for palliative treatment of breast cancer patients and has an outstanding safety profile. in addition, tamoxifen was tested in the past in boys, for other pediatric indications, and showed an excellent safety with no side effects. tamoxifen is being tested in this study, as a therapy for dmd, for the following reasons: (i) it was shown to have anti-fibrotic effect in multiple in-vivo systems; (ii) it assists in the repair of damaged muscles. in other words, tamoxifen is expected to have a synergistic effect on dmd patients, due to its dual mechanism of action. indeed, tamoxifen was shown to have significant beneficial effects in the mdx mouse model of dmd. also, a small compassionate cohort of 3 boys, treated for 6 months with tamoxifen, yielded very encouraging results.


Eligibility criteria:
inclusion criteria: * ambulatory exclusion criteria: * non ambulatory

Keywords: duchenne tamoxifen
screening patients for a strategic shift to pulmonary telerehabilitation because of covid-19

Conditions: Respiratory Disease

Summary: this study applied the pulmonary rehabilitation adapted index of self-efficacy (praise) on respiratory patients who had their on-going ambulatory pulmonary rehabilitation program interrupted due to the covid-19 outbreak. the research hypothesis is that ranking patients' self-efficacy is a useful screening tool to support patients' follow-up on a pulmonary rehabilitation telehealth solution to be explored during the covid-19 outbreak.

this was an observational study applied to a convenience sample of pulmonary rehabilitation outpatients from hospital pulido valente in lisbon, portugal, which had ambulatory treatments suspended due to the covid-19 outbreak. cross-sectional design was operationalized by a physiotherapist who promptly screened by phone a sample of 100 patients, assessing 90% of the eligible population. patients had no previous therapeutic relation with the physiotherapist, who was also blind to patient's status at the pulmonary rehabilitation program. the screening call took a mean time of 484.8 ± 173.6 seconds, which is proximately about 8 ± 3 minutes per patient, with a minimum of 5 and a maximum of 19 minutes. screening process included applying the portuguese version of the pulmonary rehabilitation adapted-index of self-efficacy (praise) and also included questioning patients if they were engaging on a daily routine of respiratory exercises by their initiative, and also if they managed to preserve a daily period to practice physical activity. in case of a positive answer, information concerning available equipment and exercise protocol adopted at patient's home environment was also collected. on a subsequent phase, data about patients' age, diagnosis referral for pulmonary rehabilitation, number of completed treatment sessions and weekly frequency, was collected from the hospital information system. statistical analysis and data management were performed using the statistical package for the social sciences (spss) version 25.0 (spss inc., chicago, il, usa). a formal sample size was not calculated since this was a convenience sample of 100 patients. descriptive statistics included mean, standard-deviation, median, quartiles, range, minimum and maximum values and frequencies presented as percentages. inferential statistics included the pearson coefficient for praise, age and number of treatment sessions, with the remaining variables analysed by the spearman coefficient. praise was the primary outcome, with mean comparison analysed by the student t test, proved the normal distribution and equal variances. a p value of less than 0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: * patients with acute respiratory disease * patients with chronic respiratory disease * patients attending a hospital-based pulmonary rehabilitation program exclusion criteria: * cognitive deficit for answering a questionnaire

Keywords: self-efficacy praise pulmonary telerehabilitation
xience v® everolimus eluting coronary stent system usa post-approval study (xience v® usa long term follow-up cohort)

Conditions: Chronic Coronary Occlusion; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis

Summary: xience v usa is a prospective, multi-center, multi-cohort post-approval study. the objectives of this study are * to evaluate xience v eecss continued safety and effectiveness during commercial use in real world settings, and * to support the food and drug administration (fda) dual antiplatelet therapy (dapt) initiative. this initiative is designed to evaluate the composite of all death, myocardial infarction (mi) and stroke (macce) and the survival of patients that are free from academic research consortium (arc) definite or probable stent thrombosis (st) and that have been treated with drug eluting stents (des) and extended dual antiplatelet therapy.

among patients enrolled in the xience v usa who have completed study phase i, some will be eligible to participate in the xience v usa long term follow-up (ltf) cohort. this ltf cohort is a prospective, open-label, multi-center, observational, single-arm study is designed to evaluate xience v eecss continued safety and effectiveness in real world settings from 1 year after the index procedure up to 5 years. the xience v usa ltf cohort will consist of the following from the initial 5,000 patients: * the first 1,500 on-label patients who are treated in accordance with the xience v eecss instruction for use (ifu), and consecutively enrolled in the xience v usa study * the remaining patients who do not participate in the hcri-dapt cohort * data monitoring committee up to two years

Eligibility criteria:
inclusion criteria: * the patient agrees to participate in this study by signing the institutional review board approved informed consent form. exclusion criteria: * the inability to obtain an informed consent. * age limit is determined by investigator. * there are no angiographic inclusion or exclusion criteria for this study.

Keywords: drug eluting stents stents angioplasty stent thrombosis